CEO: we are talking many millions
A Danish biotech company has been granted EU funds for the continued development of a malaria vaccine. The funding could be a gateway to improving other vaccines from the company as well.
In collaboration with the Dutch biotech company Mucosis and University of Copenhagen, the Danish company ExpreS2ion Biotechnologies has been awarded so-called Eurostar funding from the EU.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler:
Danish biotech company in protein deal with US company
For abonnenter
